DEF: Cullinan Therapeutics Sets 2026 Annual Meeting Date

Cullinan Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Summary

• Cullinan Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 16, 2026, at 10:00 a.m. Eastern Time.
• The meeting agenda includes the election of two Class III directors, Nadim Ahmed and Stephen Webster, for three-year terms.
• Stockholders will also vote on ratifying the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• An advisory vote on the compensation of named executive officers will also be conducted.
• The record date for determining stockholders entitled to vote is April 20, 2026.
• Proxy materials are being made available to stockholders via the Internet, with notices mailed on or about April 28, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily concerns routine corporate governance matters and does not contain significant new strategic information or financial performance updates that would strongly influence investor sentiment.

Positives

• The company is holding its annual meeting to ensure continued corporate governance and stockholder engagement.
• The virtual format of the meeting aims to facilitate broader stockholder participation.
• The board of directors is recommending the election of experienced individuals for director positions.
• KPMG LLP, a reputable accounting firm, is proposed for reappointment, indicating a commitment to financial transparency.
• The company is seeking stockholder approval on executive compensation, demonstrating a commitment to shareholder alignment.

Risks

• The company is a smaller reporting company and may be subject to scaled disclosures, potentially limiting the depth of information available.
• The filing mentions that if stockholders do not ratify the appointment of KPMG LLP, the audit committee will reconsider the appointment, implying a potential for change in auditors.
• The company's financial performance is not detailed in this proxy statement, but the 'Pay Versus Performance' section indicates net losses for 2023, 2024, and 2025, and a decline in Total Shareholder Return (TSR) in 2025.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It outlines the agenda for the upcoming annual meeting, including the election of directors, ratification of auditors, and an advisory vote on executive compensation, which are standard corporate governance procedures.

Management Comments

• "I am pleased to invite you to attend the 2026 Annual Meeting of Stockholders (the Annual Meeting) of Cullinan Therapeutics, Inc. (the Company)."
• "The meeting will be held online on June 16, 2026 at 10:00 a.m. Eastern Time."
• "Your vote is very important."
• "Your investment and continuing interest in the Company are very much appreciated."

Industry Context

StockSavvy.ai notes that this filing is a standard proxy statement for a biopharmaceutical company, outlining routine annual meeting business. The focus on director elections, auditor ratification, and executive compensation is typical for companies at this stage, reflecting ongoing efforts to maintain robust corporate governance and shareholder relations within the competitive biotech landscape.

Corporate Governance

Related Party Transactions

• Royalty Transfer Agreements with UBS Oncology Impact Fund L.P. (which beneficially owns more than five percent of outstanding common stock) through affiliated foundations. The Royalty Transfer Agreement for Cullinan Florentine remains in effect, while those for Cullinan Amber and Cullinan MICA were discontinued in November 2025 due to program discontinuation.
• Employment agreements with executive officers, which include provisions for base salary, bonus targets, and severance in case of termination without cause or resignation for good reason, particularly in the event of a change in control.
• Indemnification agreements with directors and executive officers to cover certain expenses, judgments, fines, and settlement amounts incurred in connection with their service to the company.

Stakeholder Impact

• Shareholders: Will vote on director elections, auditor ratification, and executive compensation, influencing corporate governance and executive pay alignment.
• Employees: Eligible for participation in retirement plans and benefit programs; executive officers' compensation is detailed, impacting morale and retention.
• Auditors (KPMG LLP): Their reappointment is subject to stockholder ratification, impacting their ongoing relationship with the company.
• Management: Executive compensation is subject to advisory stockholder vote, potentially influencing future compensation decisions.

Next Steps

• Stockholders are encouraged to review the proxy materials and cast their votes.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Form 8-K within four business days following the meeting.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new material financial information or strategic developments that would warrant a buy or sell recommendation. It outlines standard corporate governance procedures, director nominations, and executive compensation votes. Investors should rely on other filings for performance-based insights.

Keywords

Cullinan Therapeutics, Proxy Statement, Annual Meeting, DEF 14A, Director Election, KPMG LLP, Executive Compensation, Stockholder Vote, Corporate Governance